M Ychou

Summary

Affiliation: Institut Paoli-Calmettes
Country: France

Publications

  1. ncbi request reprint High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer
    M Ychou
    CRLC Val d Aurelle, 31 Rue de la croix verte, 34298 Montpellier Cedex 05, France
    Cancer Chemother Pharmacol 50:383-91. 2002
  2. pmc Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: a FNCLCC-ACCORD/0201 randomized phase II trial's pre-planned analysis and case report of a 5.5-year disease-free survival
    Lucie Oberic
    Institut Gustave Roussy, Villejuif, France
    Radiat Oncol 6:124. 2011
  3. pmc Reverse transcription-quantitative polymerase chain reaction: description of a RIN-based algorithm for accurate data normalization
    Alexandre Ho-Pun-Cheung
    INSERM U, Val d Aurelle Cancer Institute, Montpellier, France
    BMC Mol Biol 10:31. 2009
  4. pmc Prognostic impact of epidermal growth factor receptor (EGFR) expression on loco-regional recurrence after preoperative radiotherapy in rectal cancer
    David Azria
    Department of Radiation Oncology, Val d Aurelle Cancer Institute, Montpellier, France
    BMC Cancer 5:62. 2005
  5. pmc Fully human IgG and IgM antibodies directed against the carcinoembryonic antigen (CEA) Gold 4 epitope and designed for radioimmunotherapy (RIT) of colorectal cancers
    Veronique Garambois
    INSERM, EMI0227 Centre de Recherche en Cancérologie, CRLC Val d Aurelle Paul Lamarque, F 34298 Cedex 5 Montpellier, France
    BMC Cancer 4:75. 2004
  6. ncbi request reprint Phase-I/II radio-immunotherapy study with Iodine-131-labeled anti-CEA monoclonal antibody F6 F(ab')2 in patients with non-resectable liver metastases from colorectal cancer
    M Ychou
    Val d Aurelle Paul Lamarque Cancer Center, Montpellier, France
    Int J Cancer 75:615-9. 1998
  7. ncbi request reprint Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen
    Marc Ychou
    Digestive Oncology Unit, CRLC Val d Aurelle, Parc Euromedecine, 34298 Montpellier Cedex 5, France
    Cancer Chemother Pharmacol 52:282-90. 2003
  8. ncbi request reprint An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors
    M Ychou
    Centre Val d Aurelle, Montpellier, France
    Ann Oncol 14:481-9. 2003
  9. doi request reprint Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial
    Marc Ychou
    Centre Regional de Lutte contre le Cancer Val d Aurelle, 298 rue des apothicaires 34298 Montpellier Cedex 05, France
    J Clin Oncol 29:1715-21. 2011
  10. doi request reprint Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX
    T Mazard
    Departement d Oncologie Medicale, CHU Saint Eloi, Montpellier, France
    Cancer Chemother Pharmacol 69:807-14. 2012

Detail Information

Publications72

  1. ncbi request reprint High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer
    M Ychou
    CRLC Val d Aurelle, 31 Rue de la croix verte, 34298 Montpellier Cedex 05, France
    Cancer Chemother Pharmacol 50:383-91. 2002
    ..The efficacy and safety of single-agent, high-dose irinotecan (CPT-11, Campto) 500 mg/m(2) every 3 weeks were investigated as first-line treatment for advanced colorectal cancer (CRC)...
  2. pmc Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: a FNCLCC-ACCORD/0201 randomized phase II trial's pre-planned analysis and case report of a 5.5-year disease-free survival
    Lucie Oberic
    Institut Gustave Roussy, Villejuif, France
    Radiat Oncol 6:124. 2011
    ..We report here the results of the docetaxel plus 5 FU regimen stopped according to the interim analysis. The docetaxel plus cisplatin arm was continued...
  3. pmc Reverse transcription-quantitative polymerase chain reaction: description of a RIN-based algorithm for accurate data normalization
    Alexandre Ho-Pun-Cheung
    INSERM U, Val d Aurelle Cancer Institute, Montpellier, France
    BMC Mol Biol 10:31. 2009
    ..Normalization to accurately quantitated RNA has been proposed as the most reliable method for in vivo biopsies. However, this approach does not correct differences in RNA integrity...
  4. pmc Prognostic impact of epidermal growth factor receptor (EGFR) expression on loco-regional recurrence after preoperative radiotherapy in rectal cancer
    David Azria
    Department of Radiation Oncology, Val d Aurelle Cancer Institute, Montpellier, France
    BMC Cancer 5:62. 2005
    ..We wished to ascertain whether a correlation exists between the expression of EGFR and treatment outcome in a group of patients with rectal adenocarcinoma who had undergone preoperative radiotherapy (RT)...
  5. pmc Fully human IgG and IgM antibodies directed against the carcinoembryonic antigen (CEA) Gold 4 epitope and designed for radioimmunotherapy (RIT) of colorectal cancers
    Veronique Garambois
    INSERM, EMI0227 Centre de Recherche en Cancérologie, CRLC Val d Aurelle Paul Lamarque, F 34298 Cedex 5 Montpellier, France
    BMC Cancer 4:75. 2004
    ..Carcinoembryonic antigen (CEA) being the reference antigen for immunotargeting of these tumors, we developed human anti-CEA MAbs...
  6. ncbi request reprint Phase-I/II radio-immunotherapy study with Iodine-131-labeled anti-CEA monoclonal antibody F6 F(ab')2 in patients with non-resectable liver metastases from colorectal cancer
    M Ychou
    Val d Aurelle Paul Lamarque Cancer Center, Montpellier, France
    Int J Cancer 75:615-9. 1998
    ..This phase-I/II study demonstrated that a dose of 300 mCi of 131I-F(ab')2 from the anti-CEA Mab F6 is well tolerated with bone-marrow rescue, whereas a dose of 200 mCi can be infused without severe bone-marrow toxicity...
  7. ncbi request reprint Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen
    Marc Ychou
    Digestive Oncology Unit, CRLC Val d Aurelle, Parc Euromedecine, 34298 Montpellier Cedex 5, France
    Cancer Chemother Pharmacol 52:282-90. 2003
    ..The aim of this phase II study was to determine the efficacy and tolerability of the bimonthly, pharmacokinetically intensified LV5FU2 regimen in the treatment of metastatic colorectal cancers...
  8. ncbi request reprint An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors
    M Ychou
    Centre Val d Aurelle, Montpellier, France
    Ann Oncol 14:481-9. 2003
    ..The aim of this study was to determine the maximum-tolerated dose (MTD) and the recommended dose of irinotecan and oxaliplatin with a fixed 5-fluorouracil (5-FU)/leucovorin (LV) regimen in patients with metastatic solid tumors...
  9. doi request reprint Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial
    Marc Ychou
    Centre Regional de Lutte contre le Cancer Val d Aurelle, 298 rue des apothicaires 34298 Montpellier Cedex 05, France
    J Clin Oncol 29:1715-21. 2011
    ..This phase III trial was designed to evaluate the benefit in overall survival (OS) of perioperative fluorouracil plus cisplatin in resectable gastroesophageal adenocarcinoma...
  10. doi request reprint Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX
    T Mazard
    Departement d Oncologie Medicale, CHU Saint Eloi, Montpellier, France
    Cancer Chemother Pharmacol 69:807-14. 2012
    ..Biweekly schedule of capecitabine combined with irinotecan (XELIRI), consecutively with irinotecan and oxaliplatin (XELIRINOX), was evaluated in patients with metastatic cancer from any solid tumors...
  11. ncbi request reprint Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatment
    E Samalin
    CRLC Val d Aurelle, 208, rue des Apothicaires, 34298 Montpellier Cedex 5, France
    Clin Res Hepatol Gastroenterol 35:48-54. 2011
    ..We evaluated the efficacy of FOLFIRI regimen in a large retrospective series of MGA pts...
  12. ncbi request reprint Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases
    M Ychou
    Centre Regional de Lutte contre le Cancer Val d Aurelle, 208 Rue des Apothicaires, 34298, Montpellier Cedex 05, France
    Cancer Chemother Pharmacol 62:195-201. 2008
    ..To assess the rate of R(0) resection of liver metastases achieved after chemotherapy with FOLFIRINOX...
  13. doi request reprint A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802)
    M Ychou
    Centre de Recherche et de Lutte contre le Cancer Val d Aurelle, Montpellier, France
    Ann Oncol 20:674-80. 2009
    ..This multicenter adjuvant phase III trial evaluated the addition of irinotecan to LV5FU2 in colon cancer patients at high risk of relapse...
  14. ncbi request reprint Enhancement of radiation therapy by tumor necrosis factor alpha in human colon cancer using a bispecific antibody
    David Azria
    INSERM EMI0227 Tumor Biology and Antibody Engineering, CNRS GDR2352, Marseille, Montpellier, France
    Int J Radiat Oncol Biol Phys 55:1363-73. 2003
    ..027), whereas TNFalpha, BAb, or BAb + TNFalpha had no effect. BAb + TNFalpha + RT combination enhanced the delay for the tumor to reach 2000 mm(3) as compared with RT alone (p = 0.033, for BAb + TNFalpha + RT group vs. RT group)...
  15. ncbi request reprint Chemotherapy in carcinomas of unknown primary site: a high-dose intensity policy
    S Culine
    Centre Regional de Lutte contre le Cancer Val d Aurelle, Montpellier, France
    Ann Oncol 10:569-75. 1999
    ..Unknown primary tumors are highly malignant diseases which portend a dire prognosis. We designed a prospective high dose-intensity policy with the aim of improving the results obtained with conventional chemotherapy...
  16. doi request reprint A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer
    M Ychou
    CRLC Val d Aurelle, Montpellier, France
    Ann Oncol 20:1964-70. 2009
    ..This phase III trial compared FOLFIRI with simplified 5-FU/FA in this setting...
  17. ncbi request reprint Neoadjuvant treatment in upper gastrointestinal adenocarcinomas: new paradigms from old concepts?
    Emmanuelle Samalin
    Department of Digestive Oncology, CRLC Val d Aurelle, Montpellier, France
    Curr Opin Oncol 19:384-9. 2007
    ..This article reviews data on neoadjuvant and perioperative treatment modalities for upper gastrointestinal adenocarcinomas...
  18. doi request reprint A large-scale candidate gene approach identifies SNPs in SOD2 and IL13 as predictive markers of response to preoperative chemoradiation in rectal cancer
    A Ho-Pun-Cheung
    Department of Biology, Val d Aurelle Cancer Institute, Montpellier, France
    Pharmacogenomics J 11:437-43. 2011
    ..005) and interleukin-13 (IL13) rs1800925 (P=0.0008) were significantly associated with tumor response to chemoradiation. These results reinforce the idea of using germline polymorphisms for personalized treatment...
  19. ncbi request reprint 5-fluorouracil and leucovorin as second-line chemotherapy in carcinomas of unknown primary site
    S Culine
    Centre Regional de Lutte Contre le Cancer, Val d Aurelle, Montpellier, France
    Anticancer Res 21:1455-7. 2001
    ..From the start of second-line chemotherapy, the median overall survival was 3 months. The median overall survival from diagnosis was 9 months. Second-line chemotherapy with 5-FU/LV has no impact on survival in patients with CUP...
  20. ncbi request reprint ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases
    Laurent Candeil
    CNRS UMR 5160, Centre de Recherche en Cancerologie, CRLC Val d Aurelle, Montpellier, France
    Int J Cancer 109:848-54. 2004
    ..In conclusion, this study supports the potential involvement of ABCG2 in the development of irinotecan resistance in vivo...
  21. pmc Adjuvant radioimmunotherapy trial with iodine-131-labeled anti-carcinoembryonic antigen monoclonal antibody F6 F(ab')2 after resection of liver metastases from colorectal cancer
    Marc Ychou
    Institut de Recherche en Cancérologie de Montpellier, CRLC Val d Aurelle Paul Lamarque, 34298 Montpellier Cedex 5, France
    Clin Cancer Res 14:3487-93. 2008
    ..Ten patients with tumor-to-normal liver ratios of >5 and three others were treated with a therapeutic injection [180-200 mCi 131I/50 mg F(ab')2] 30 to 64 days after surgery...
  22. pmc Involvement of circulating CEA in liver metastases from colorectal cancers re-examined in a new experimental model
    A Leconte
    , CRLC Val d Aurelle Paul Lamarque Cancer Centre, , Montpellier, France
    Br J Cancer 80:1373-9. 1999
    ....
  23. ncbi request reprint Pharmacokinetics and pharmacodynamics of irinotecan and its metabolites from plasma and saliva data in patients with metastatic digestive cancer receiving Folfiri regimen
    Sylvain Poujol
    Oncopharmacology Department, Pharmacy Service, Val d Aurelle Anticancer Centre, Parc Euromedecine, Montpellier, France
    Cancer Chemother Pharmacol 58:292-305. 2006
    ..We hypothesized that saliva, a noninvasive, safe and painless biological sampling process, could be a good predictor of the behavior of irinotecan and its metabolites...
  24. doi request reprint [Impact of mutational status of KRAS in the care of patients with colorectal cancer metastasis]
    E Assenat
    CHU de Montpellier, CRLC Val d Aurelle, Service d Oncologie Digestive, 525, Rue de la Croix Verte, 34094 Montpellier, France
    Bull Cancer 96:S41-6. 2009
    ..In this article, we review the role and impact of mutational status of KRAS in the care of patients with colorectal cancer metastasis...
  25. ncbi request reprint [Contribution of endorectal ultrasonography in preoperative evaluation for very low rectal cancer]
    P Senesse
    CRLC Val d Aurelle, Montpellier
    Gastroenterol Clin Biol 25:24-8. 2001
    ..Pretherapeutic evaluation of locoregional extension relies mainly on digital rectal examination. The interest of endorectal ultrasonography to assess lateral and inferior margins is still to be determined...
  26. ncbi request reprint [Concomitant use of radiotherapy and gemcitabine: preclinical findings and clinical practice]
    D Azria
    Département d Oncologie Radiothérapie, CRLC Val d Aurelle, 34298 Montpellier, France
    Cancer Radiother 8:S106-13. 2004
    ..This review summarizes the mechanisms of interaction between radiotherapy and gemcitabine and presents several therapeutic schemes for each tumor location...
  27. pmc p53 status and response to radiotherapy in rectal cancer: a prospective multilevel analysis
    E Lopez-Crapez
    Cancer Research Center, Val d Aurelle Cancer Institute, Montpellier 34298, France
    Br J Cancer 92:2114-21. 2005
    ..Our results do not support the use of p53 alterations alone as a predictive marker for response to radiotherapy in rectal carcinoma...
  28. pmc Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer
    T Conroy
    Centre Alexis Vautrin and Nancy University, EA 4360, Vandoeuvre lès Nancy 54511, France
    Br J Cancer 102:59-67. 2010
    ..A secondary objective was to compare the quality of life (QoL) and health-care satisfaction of patients...
  29. ncbi request reprint Clinical impact of intesified 5-Fluorouracil-based chemotherapy using a prospective pharmacokinetically-guided dosing approach: comparative study in elderly and non-elderly patients with metastatic colorectal cancer
    J Duffour
    Department of Digestive Oncology, Val d Aurelle Regional Cancer Center Montpellier Cedex, France
    J Chemother 22:179-85. 2010
    ..509) and even to double it in half of the patients of both groups. Aging did not seem to limit intensified chemotherapy or to affect the pK behavior of the 5-FU...
  30. ncbi request reprint Docetaxel and radiotherapy and pancreatic cancer
    F Viret
    Department of Medicine, Institut Paoli Calmettes, Marseille, France
    Pancreas 27:214-9. 2003
    ..We conducted a phase 1 trial to determine the maximum tolerated dose (MTD) of weekly docetaxel delivered concurrently with radiation therapy for the treatment of locally advanced adenocarcinoma of the pancreas...
  31. doi request reprint Cost-minimisation analysis in first-line treatment of metastatic colorectal cancer in France: XELOX versus FOLFOX-6
    G Perrocheau
    Centre Rene Gauducheau, centre d investigation clinique, Saint Herblain, France
    Oncology 79:174-80. 2010
    ..The objective of this additional analysis was to compare the cost of XELOX and FOLFOX-6...
  32. ncbi request reprint Multicentre phase II study using increasing doses of irinotecan combined with a simplified LV5FU2 regimen in metastatic colorectal cancer
    Jacqueline Duffour
    Digestive Department, CRLC Val d Aurelle Parc Euromédecine, 34298 Montpellier Cedex 5, France
    Cancer Chemother Pharmacol 60:383-9. 2007
    ..This phase II study aimed to assess whether increasing the irinotecan dose in the first line FOLFIRI regimen would benefit mCRC patients...
  33. ncbi request reprint [An unusual liver metastasis]
    Frederic Bibeau
    Service d Anatomie Pathologique, CRLC Val d Aurelle, Cedex 5
    Ann Pathol 26:455-6. 2006
  34. doi request reprint FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer
    Thierry Conroy
    Nancy University and Department of Medical Oncology, Centre Alexis Vautrin, Nancy, France
    N Engl J Med 364:1817-25. 2011
    ....
  35. ncbi request reprint Small cell carcinoma with concomitant adenocarcinoma arising in a Barrett's oesophagus: report of a case with a favourable behaviour
    Frederic Bibeau
    Department of Pathology, Centre Regional de Lutte contre le Cancer Val d Aurelle, 208 Rue des Apothicaires, Montpellier Cedex 5, France
    Virchows Arch 452:103-7. 2008
    ..Moreover, it is particular because of its favourable behaviour, with a 6-year disease-free survival, after neoadjuvant chemoradiation, surgery and postoperative chemotherapy...
  36. doi request reprint Inter-observer agreement between dermatologists and oncologists in assessing dermatological toxicities in patients with metastatic colorectal cancer treated by cetuximab-based chemotherapies: a pilot comparative study
    Jacqueline Duffour
    Department of Digestive Oncology, Val d Aurelle, Regional Cancer Centre, Montpellier Cedex 5, France
    Eur J Cancer 46:3169-74. 2010
    ..Better training of oncologists by using a dermatological atlas would improve inter-observer agreement...
  37. doi request reprint Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan
    Frederic Bibeau
    Departement de Pathologie, Centre régional de lutte contre le cancer Val d Aurelle Paul Lamarque, 208 Rue des Apothicaires, Parc Euromedecine, 34298 Montpellier Cedex 05 France
    J Clin Oncol 27:1122-9. 2009
    ..We investigated the association of FcgammaR polymorphisms and KRAS mutation with the outcome of irinotecan-refractory mCRC patients treated with cetuximab plus irinotecan...
  38. ncbi request reprint Safety of cisplatin combined with continuous 5-FU versus bolus 5-FU and leucovorin, in metastatic gastrointestinal cancer (FFCD 9404 randomised trial)
    Jacqueline Duffour
    CRLC Val d Aurelle Paul Lamarque, 34298 Montpellier, France
    Anticancer Res 26:3877-83. 2006
    ..FP (5-FU combined with Cisplatin) as a first line chemotherapy in advanced oesophageal, gastric and pancreatic cancer...
  39. ncbi request reprint Surgery for esophageal cancer after concomitant radiochemotherapy: oncologic and functional results
    Nicolas Plaisant
    Department of Surgical Oncology, Centre Regional de Lutte Centre le Cancer, 208 Rue des Apothicaires, Parc Euromedecine, 34298 Montpellier Cedex 5, France
    World J Surg 29:32-8. 2005
    ..Only surgical resection can provide accurate prognostic information for staging esophageal cancer and improving local control...
  40. ncbi request reprint [External beam radiation therapy and interstitial brachytherapy in the treatment of anal canal carcinomas: a series of 70 patients]
    Jean Bernard Dubois
    Departement de Radiotherapie, CRLC Val d Aurelle, 34298 Montpellier
    Bull Cancer 90:1107-10. 2003
    ....
  41. ncbi request reprint Combined radiotherapy, 5-fluorouracil continuous infusion and weekly oxaliplatin in advanced rectal cancer: a phase I study
    Eric Francois
    Department of Medical Oncology, Centre Antoine Lacassagne, Avenue de Valombrose, 06189 Nice, Cedex 2, France
    Eur J Cancer 41:2861-7. 2005
    ..The good safety profile of the regimen, associated with promising results in terms of histological response, suggest that the regimen could be developed in future phase II/III studies...
  42. ncbi request reprint Gemcitabine and docetaxel after failure of cisplatin-based chemotherapy in patients with carcinoma of unknown primary site
    Damien Pouessel
    Centre Régional de Lutte contre le Cancer Val d Aurelle Montpellier, Parc Euromedecine, 34298 Montpellier, France
    Anticancer Res 23:2801-4. 2003
    ..We evaluated the activity of a chemotherapy regimen combining gemcitabine and docetaxel in patients who primarily failed cisplatin-based chemotherapy...
  43. ncbi request reprint [Vascular hepatic injury following neoadjuvant treatment for a cardial adenocarcinoma]
    Frederic Bibeau
    Service d Anatomie Pathologique, CRLC Val d Aurelle, Montpellier
    Gastroenterol Clin Biol 30:611-3. 2006
    ..Vascular damage may remain histological, as in our case. But one should be aware that vascular injuries could influence hepatic function and regeneration after wide hepatectomy as well as extensive fibrosis...
  44. ncbi request reprint Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil and cisplatin
    David Azria
    Department of Radiation Oncology, Val d Aurelle Paul Lamarque Cancer Institute, Montpellier, France
    Pancreas 25:360-5. 2002
    ..AIM To assess tumor control and the palliative benefit of 5-fluorouracil (5-FU), cisplatin (CDDP), and radiotherapy in patients with advanced pancreatic cancer...
  45. ncbi request reprint [Irinotecan for the treatment of metastatic colorectal cancer]
    Eric Assenat
    CRLC Val d Aurelle Paul Lamarque, 208 Rue des Apothicaires, Parc Euromedecine, 34298 Montpellier Cedex 5
    Bull Cancer 93:507-15. 2006
    ..Nevertheless this strategy must again show a true clinical interest. Finally they are at promising developments in the fields of the irinotecan pharmacogenetic and pharmacogenomic...
  46. ncbi request reprint [Gemcitabine and ionizing radiations: radiosensitization or radio-chemotherapy combination]
    David Azria
    Département d Oncologie Radiothérapie, CRLC Val d Aurelle Paul Lamarque, Rue de la Croix Verte, 34298 Montpellier Cedex 05, France
    Bull Cancer 89:369-79. 2002
    ..Gemcitabine surely is a strong radiosensitizer even at low doses with future extended combined modality therapeutic indications. The ultimate goal of combined treatments should be an increased therapeutic ratio...
  47. ncbi request reprint Alternative bimonthly cycles of doxorubicin, cyclophosphamide, and etoposide, cisplatin with hematopoietic growth factor support in patients with carcinoma of unknown primary site
    Stephane Culine
    Centre Regional de Lutte contre le Cancer Val d Aurelle, Montpellier, France
    Cancer 94:840-6. 2002
    ....
  48. pmc Assessment of epidermal growth factor receptor (EGFR) expression in primary colorectal carcinomas and their related metastases on tissue sections and tissue microarray
    Frederic Bibeau
    Department of Pathology, Centre Regional de Lutte contre le Cancer Val d Aurelle, 34298, Montpellier, Cedex 5, France
    Virchows Arch 449:281-7. 2006
    ..In conclusion, EGFR expression measured in tissue sections from primary CRC and their related metastases was found to be similar and frequent, but it was significantly underestimated by the TMA technique...
  49. pmc Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan
    Maguy Del Rio
    Centre National de la Recherche Scientifique Unité Mixte de Recherche 5160, Service d Anatomie Pathologique, Service d Oncologie Digestive, Montpellier, France
    J Clin Oncol 25:773-80. 2007
    ..A major clinical challenge is to identify the subset of patients who could benefit from this chemotherapy. We aimed to identify a gene expression profile in primary colon cancer tissue that could predict chemotherapy response...
  50. doi request reprint Intra-operative radiotherapy of rectal cancer: results of the French multi-institutional randomized study
    Jean Bernard Dubois
    CRLC Val d Aurelle Paul Lamarque, 208 Rue des Apothicaires, Montpellier Cedex 5, France
    Radiother Oncol 98:298-303. 2011
    ..To assess efficacy and tolerance of intra-operative radiation therapy (IORT) in patients suffering from locally advanced rectal cancer, treated with preoperative radiotherapy followed by surgical resection...
  51. ncbi request reprint Sensitive HPLC-fluorescence method for irinotecan and four major metabolites in human plasma and saliva: application to pharmacokinetic studies
    Sylvain Poujol
    Oncopharmacology Department, Pharmacy Service, Val d Aurelle Anticancer Centre, Parc Euromedecine, 34298 Montpellier, Cedex 5, France
    Clin Chem 49:1900-8. 2003
    ..Camptothecin was used as internal standard...
  52. ncbi request reprint Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site
    Damien Pouessel
    Department of Medical Oncology, Centre Regional de Lutte contre le Cancer Val d Aurelle, Montpellier, France
    Cancer 100:1257-61. 2004
    ..The current study was performed to evaluate the efficacy and toxicity of a noncisplatin-based chemotherapy regimen combining gemcitabine and docetaxel as front-line chemotherapy for patients with carcinoma of an unknown primary site...
  53. ncbi request reprint Hepatic metastases from carcinomas of unknown primary site
    Damien Pouessel
    Departement d Oncologie Medicale, Centre Regional de Lutte contre le Cancer Val d Aurelle, Parc Euromedecine, 34298 Montpellier Cedex 5
    Gastroenterol Clin Biol 29:1224-32. 2005
    ..Hepatic metastases are often present at diagnosis of carcinoma of unknown primary site (CUP). The objective of this study was to describe the diagnostic and therapeutic strategies used...
  54. ncbi request reprint Impact of RNA degradation on gene expression profiles: assessment of different methods to reliably determine RNA quality
    Virginie Copois
    CNRS UMR 5160, CRLC Val d Aurelle, Montpellier, France
    J Biotechnol 127:549-59. 2007
    ..The combination of these methods, allowing monitoring of RNA quality prior to and after the hybridization experiments, ensured reliable and reproducible microarray data...
  55. ncbi request reprint Radiation recall: a well recognized but neglected phenomenon
    David Azria
    Department of Radiation Oncology, Val d Aurelle Paul Lamarque Cancer Institute, Montpellier, France
    Cancer Treat Rev 31:555-70. 2005
    ..Although skin has been the major site of radiation recall toxicity, instances involving other organ have been reported...
  56. ncbi request reprint [Radiotherapy and inhibitors of epidermal growth factor receptor: preclinical findings and preliminary clinical trials]
    David Azria
    Département d Oncologie Radiothérapie, Laboratoire d immunociblage des tumeurs et ingénierie des anticorps, EMI 0227, CRLC Val d Aurelle Paul Lamarque, 34298 Montpellier
    Bull Cancer 90:S202-12. 2003
    ..Finally, EGF receptor family member inhibitors may themselves be effective radiosensitizers and their use in future clinical investigations are based on a solid radiobiological rational...
  57. ncbi request reprint Drug specific resistance to oxaliplatin is associated with apoptosis defect in a cellular model of colon carcinoma
    Isabelle Gourdier
    CNRS UMR 5094, Faculte de Pharmacie, 15 Avenue Charles Flahaut, P O Box 14491, 34093 Montpellier, France
    FEBS Lett 529:232-6. 2002
    ..Taken together, these findings suggest that altered mitochondrial-mediated apoptosis could play a role in oxaliplatin resistance...
  58. ncbi request reprint [Gemcitabine and pancreatic cancer]
    Patricia Prost
    Service d Oncologie Digestive, CRLC Val d Aurelle Paul Lamarque, Parc Euromedecine, 34298 Montpellien
    Bull Cancer 89:S91-5. 2002
    ..Current studies are now also being directed towards an association between gemcitabine and other cytotoxics, like cisplatinum or oxaliplatin...
  59. ncbi request reprint Towards a pan-European consensus on the treatment of patients with colorectal liver metastases
    Eric Van Cutsem
    University Hospital Gasthuisberg, Digestive Oncology Unit, Leuven, Belgium
    Eur J Cancer 42:2212-21. 2006
    ....
  60. ncbi request reprint Relationship of serum bilirubin to toxicity in patients with metastatic colorectal cancer treated with single-agent high-dose irinotecan
    Andrew Kramar
    J Clin Oncol 23:650; author reply 650-1. 2005
  61. ncbi request reprint Cancer of the stomach
    Denis Pezet
    Service de Chirurgie, CHU, Clermont Ferrand
    Gastroenterol Clin Biol 30:2S16-2S23. 2006
  62. ncbi request reprint Feasibility of preoperative combined radiation therapy and chemotherapy with 5-fluorouracil and cisplatin in potentially resectable pancreatic adenocarcinoma: The French SFRO-FFCD 97-04 Phase II trial
    Francoise Mornex
    département de radiothérapie oncologie, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon France
    Int J Radiat Oncol Biol Phys 65:1471-8. 2006
    ..Neoadjuvant chemoradiotherapy might offer potential benefits regarding local and systemic control and survival. This multi-institutional Phase II trial explored the feasibility of preoperative chemoradiation in this situation...
  63. ncbi request reprint UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan
    Jean Francois Cote
    Institut National de la Sante et de la Recherche Medicale UMR S775, Bases Moléculaires de la Réponse aux Xénobiotiques, Universite Paris Descartes, Assistance Publique Hopitaux de Paris, France
    Clin Cancer Res 13:3269-75. 2007
    ....
  64. ncbi request reprint Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group
    Bernard Nordlinger
    Hopital Ambroise Pare, CHU Paris Ouest, 92100 Boulogne Cedex, France
    Eur J Cancer 43:2037-45. 2007
    ....
  65. ncbi request reprint A limited sampling strategy to estimate the pharmacokinetic parameters of irinotecan and its active metabolite, SN-38, in patients with metastatic digestive cancer receiving the FOLFIRI regimen
    Sylvain Poujol
    Oncopharmacology Department, Pharmacy Service, Faculty of Pharmacy, University Montpellier I, 34093 Montpellier Cedex 5, France
    Oncol Rep 18:1613-321. 2007
    ..The limited sampling strategy developed in this study ought to facilitate future studies on the pharmacology and toxicity of irinotecan-based therapy...
  66. ncbi request reprint Epirubicin-docetaxel in advanced gastric cancer: two phase II studies as second and first line treatment
    Suzanne Nguyen
    Service d Oncologie, Centre Hospitalier, 40 avenue Léon Blum, 60021 Beauvais Cedex, France
    Bull Cancer 93:E1-6. 2006
    ..We report here the results of these two phase II studies...
  67. ncbi request reprint Neoadjuvant chemoradiotherapy in esophageal cancer: is it still the question?
    Bruno Pereira
    J Clin Oncol 26:5133-4; author reply 5134. 2008
  68. ncbi request reprint Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer
    Michel Ducreux
    Gastrointestinal Unit, Institut Gustave Roussy, 94805 Villejuif Cedex, France
    J Clin Oncol 23:4881-7. 2005
    ....
  69. ncbi request reprint [Clinical Practice Guidelines 2004. Standards, Options and Recommendations for the management of patient with adenocarcinoma of the stomach: radiotherapy (therapeutic evaluation)]
    Marc Ychou
    Centre Val d Aurelle, Montpellier
    Bull Cancer 92:381-409. 2005
    ..The main objective is the development of clinical practice guidelines to improve the quality of health care and the outcome of cancer patients...
  70. doi request reprint KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab
    Astrid Lievre
    L Institut National de la Santé et de la Recherche Médicale U775, Universite Paris Descartes, 45 Rue des Saints Peres, 75006 Paris, France
    J Clin Oncol 26:374-9. 2008
    ..The aim of this study was to validate, in an independent larger series of 89 patients, the prognostic value of KRAS mutations on response to cetuximab and survival...
  71. ncbi request reprint Cyclin D1 gene G870A polymorphism predicts response to neoadjuvant radiotherapy and prognosis in rectal cancer
    Alexandre Ho-Pun-Cheung
    INSERM U860, and Department of Oncobiology, Val d Aurelle Cancer Institute, 208 Rue des Apothicaires, 34298 Montpellier, France
    Int J Radiat Oncol Biol Phys 68:1094-101. 2007
    ..To investigate whether CCND1 genetic variations associated with a constitutive nuclear protein may influence either the pathologic response to preoperative RT or the prognosis in a series of rectal cancer patients...
  72. ncbi request reprint Initial endoscopic description of esophageal squamous cell carcinomas
    Victoire Granger
    Service de Médecine Interne E, CHU Saint Eloi, Montpellier
    Gastroenterol Clin Biol 30:1365-70. 2006
    ..We wanted to develop a standard model for the endoscopy report which could be used in routine practice...